Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test

Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test

Source: 
EP Vantage
snippet: 

Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.